Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinic…

Biotechnology

US, San Diego [HQ]

Overview
Fin. Reports
Financials
Leadership & Strategy
Government, Law & Regulation
Employees
More

Earnings Call · Transcripts · Speakers

Earnings Call Transcripts

Earnings Call · Transcripts · Speakers

This analysis tool shows transcript versions of the official earnings calls hosted by Mirati Therapeutics, Inc.

Could not find a transcript

Transcripts

Could not find a transcript

Peers Transcripts

Peers Analysis

Sorry! None of MRTX's peers has listed transcripts.

SEC Reader

The document search tool might be interesting as well.
Give it a try, to quickly access SEC Filings-

10-K · 10-Q · DEF 14A · S-4

Upcoming Transcript Tools

Full Text Search - Across All Transcripts
Detail Speaker Profiles
Non-US Transcripts